University of South Florida

Digital Commons @ University of South Florida
Internal Medicine Faculty Publications

Internal Medicine

2015

Deep Venous Thrombosis with Pulmonary Embolism Related to
IVIg Treatment: A Case Report and Literature Review
Michael T. Flannery
University of South Florida, mflanner@usf.edu

Deborah Humphrey
University of South Florida, dhumphre@usf.edu

Follow this and additional works at: https://digitalcommons.usf.edu/intmed_facpub

Scholar Commons Citation
Flannery, Michael T. and Humphrey, Deborah, "Deep Venous Thrombosis with Pulmonary Embolism
Related to IVIg Treatment: A Case Report and Literature Review" (2015). Internal Medicine Faculty
Publications. 158.
https://digitalcommons.usf.edu/intmed_facpub/158

This Article is brought to you for free and open access by the Internal Medicine at Digital Commons @ University of
South Florida. It has been accepted for inclusion in Internal Medicine Faculty Publications by an authorized
administrator of Digital Commons @ University of South Florida. For more information, please contact
scholarcommons@usf.edu.

Hindawi Publishing Corporation
Case Reports in Medicine
Volume 2015, Article ID 971321, 3 pages
http://dx.doi.org/10.1155/2015/971321

Case Report
Deep Venous Thrombosis with Pulmonary Embolism Related to
IVIg Treatment: A Case Report and Literature Review
Michael T. Flannery and Deborah Humphrey
University of South Florida Morsani College of Medicine, 12901 Bruce B Downs Boulevard, MDC Box 19,
Room L1041, Tampa, FL 33612, USA
Correspondence should be addressed to Michael T. Flannery; mflann5555@aol.com
Received 26 January 2015; Revised 6 May 2015; Accepted 7 May 2015
Academic Editor: Masahiro Kohzuki
Copyright © 2015 M. T. Flannery and D. Humphrey. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
IVIg therapy has potentially been related to arterial and venous therapy. We performed an Ovid review focusing on IVIg and
thrombotic events. While a few case reports were reviewed case series and case control studies were particularly reviewed in relation
to thrombotic events. Outcomes demonstrate a correlation between underlying cardiovascular risk factors with predominately
arterial events which typically occurred within 4–24 hours of infusion. While venous events occurred less commonly they were
associated with traditional risk factors and occurred later, typically, 1–7 days following infusion of IVIg. Potential causation of
thrombotic events was discussed.

1. Introduction
The utilization of IVIg (Intravenous Immunoglobulin) is
commonly prescribed for a multitude of predominately
autoimmune hematologic and neurologic diseases. It has
been estimated that more than 50% of cases involve offlabel use [1]. Studies, to date, demonstrate arterial or venous
thrombosis in approximately 10–15% of cases dependent on
specific patient risk variables [2–4]. Our case involves the
development of a large proximal deep venous thrombosis (DVT) with a pulmonary embolism in a patient who
had received approximately 1 year of IVIg for Primary
Lateral Sclerosis (PLS) and possible Stiff Person Syndrome
(SPS). Traditional risk factors included obesity, hypertriglyceridemia, and age (53 years). Other potential risk factors
included the presence of a monoclonal kappa gammopathy
and the usage of intramuscular Testosterone therapy for
central hypogonadism.

2. Case Report
A 53-year-old Caucasian male with a 2-year history of PLS
and SPS presented with right thigh pain and shortness of
breath. His history included predominately upper motor

neuron findings including muscle pain, spastic muscle tone,
and muscle spasms diffusely. His antibodies were positive
for glutamic acid decarboxylase (GAD) suggesting a possible
component of SPS. He was placed on IVIg 0.7 g/kg over
two days every three weeks which decreased his spasms and
improved his quality of life. His work-up also included the
finding of a mild increased kappa monoclonal gammopathy
with a normal bone marrow biopsy. He developed his thigh
pain acutely one week after his most recent IVIg infusion.
The patient had no personal or family history of thrombotic
events (TE). His exam demonstrated a normal cardiopulmonary exam with his neurologic exam demonstrating spastic tone with hyperreflexia in the lower extremity with pain on
palpation of the posterior right thigh. No swelling, redness, or
cords were noted. The patient had a positive Babinski on the
left foot. Lower extremity Doppler confirmed a large femoral
DVT on the right with a positive computed tomography
angiography study for a right pulmonary embolus. Laboratory investigation of coagulation and routine labs were all
normal. The patient remained hemodynamically stable with
no A-a gradient and was placed on rivaroxaban orally for an
initially planned course of 6 months. A thrombophilia workup for Antithrombin III, Protein C/S activity, Factor 5 Leiden,
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Prothrombin mutation, and Antiphospholipid antibodies
and homocysteine levels were all normal.

3. Discussion
There have been a few case reports and at least one review
and one case control study of TE with IVIg usage [2–6]. In the
literature review of IVIg associated TE 65 cases were reviewed
in the literature with a median age of 63 years [2].
Cardiovascular risk factors were common including
hypertension, coronary artery disease, diabetes mellitus, and
hyperlipidemia. Arterial thrombosis (myocardial infarction
and stroke) was four times more common than venous
thrombosis [2]. Underlying risk factors for venous thrombosis were obesity and immobility while risk factors for arterial
thrombosis were hypertension, coronary artery disease, and
age. There have also been positive results from IVIg infusion
for SPS and vasculature complications, such as stroke, have
been rarely life threatening [3]. Case reports of TE with
IVIg encouraged the Food and Drug Administration (FDA)
to add a precautionary statement to the labeling of IVIg
products in 2002. Other than the 65 patients discussed in
the review, the authors also documented six cases of TE
related to IVIg at their institution [2]. However, three of
their patients had underlying thrombophilia risk factors and
another was not tested. The study also found that when 2 or
more cardiovascular risk factors were present the odds ratio
for a TE event was 1.39; however, with 4 or more risk factors
the odds ratio went up to 10.5. It also found 11.8% of TE
within 2 weeks of IVIg infusion similar to a literature review
which found 13% of TE related to IVIg infusion [4]. There was
no difference in 30-day mortality between case and controls;
however, the mortality rate was 16–18% [2]. Other studies
looked at the timing of TE and found that arterial events
were more common in 4–24 hours following infusion while
venous events occurred more commonly 1–7 days following
infusion [4, 5]. Venous events were definitely more common
in patients with cannulated lines requiring line removal and
anticoagulation [6]. Underlying risk factors may certainly
cause a difference in whether patients have an arterial versus
a venous event and their timing.
Several theories have been discussed for causation of
TE in patients receiving IVIg. The first and foremost is the
increase in serum viscosity which then declines gradually
over one month. One study found that the serum viscosity
can increase as high as 2.9 cp (normal 1.5–1.9 cp) immediately following infusion [7]. Other mechanisms include
the promotion of RBC aggregation [8] or leukocyte-platelet
aggregation [9], activation of factor XI [10], and increased
vasomotor tone based on Doppler flow [11, 12].
Given our patient’s history of mild kappa monoclonal
gammopathy and increased triglycerides (type IV hyperlipidemia) a baseline serum viscosity should have been obtained.
In addition, the FDA has recently warned physicians about
the potential of TE in men on Testosterone therapy. Our
patient was receiving 300 mg of Depo-Testosterone every 2
weeks intramuscularly. The most recent dose administered
1 week prior to his DVT/PE was administered to his right
lateral quadricep region. In a recent review of Testosterone
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therapy and TE the majority of patients had an underlying
undiagnosed thrombophilia or hypofibrinolysis [13]. The
authors recommended a thrombophilia work-up in men with
androgen deficiency requiring Testosterone therapy. Our
patient’s thrombophilia work-up was negative, however.

4. Summary
It appears that patients who require IVIg who have cardiovascular risk factors or risk factors for venous thrombosis
should have a discussion of the risk/benefit ratio and be made
aware of the 11–13% rate of TE in patients with defined risk
factors who require IVIg therapy. In addition, patients at
risk for hyperviscosity (monoclonal gammopathy, increased
triglycerides/chylomicrons, cryoglobulinemia, etc.) have a
baseline serum viscosity obtained before starting therapy.
Avoiding high dose infusions (400–1000 mg/kg/day) and
giving dosing infusions over several hours may also reduce
risk [14].
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[6] L. Darnige and A. Lillo-Le Louët, “Treatments with immunoglobulin and thrombotic adverse events,” Revue de Medecine
Interne, vol. 35, no. 1, pp. 39–44, 2014.
[7] M. C. Dalakas, “High-dose intravenous immunoglobulin and
serum viscosity: risk of precipitating thromboembolic events,”
Neurology, vol. 44, no. 2, pp. 223–226, 1994.
[8] R. Ben-Ami, G. Barshtein, T. Mardi et al., “A synergistic effect
of albumin and fibrinogen on immunoglobulin-induced red
blood cell aggregation,” The American Journal of Physiology—
Heart and Circulatory Physiology, vol. 285, no. 6, pp. H2663–
H2669, 2003.

Case Reports in Medicine
[9] B. M. Lapointe, L. M. Herx, V. Gill, L. M. Metz, and P. Kubes,
“IVIg therapy in brain inflammation: etiology-dependent differential effects on leucocyte recruitment,” Brain, vol. 127, no.
12, pp. 2649–2656, 2004.
[10] A. S. Wolberg, R. H. Kon, D. M. Monroe, and M. Hoffman, “Coagulation factor XI is a contaminant in intravenous
immunoglobulin preparations,” American Journal of Hematology, vol. 65, no. 1, pp. 30–34, 2000.
[11] R. Sztajzel, J. L. Floch-Rohr, and P. Eggimann, “High-dose intravenous immunoglobulin treatment and cerebral vasospasm: a
possible mechanism of ischemic encephalopathy?” European
Neurology, vol. 41, no. 3, pp. 153–158, 1999.
[12] R. Voltz, F. V. Rosen, T. Yousry, J. Beck, and R. Hohlfeld,
“Reversible encephalopathy with cerebral vasospasm in a
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